Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | Director · Executive Chair of the Board | March 10, 2024 | March 12, 2024 |
| STRYKER CORPSYK · Entity 369 | Director | May 06, 2026 | May 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date March 10, 2024 · Filed March 12, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 432,266.333 |
Ending reported balance
After 2024-03-10 transaction · row 9
9 source rows · reconciled sequenceRow 1 · 2024-03-10 · Exercise / conversion · Acquired 23,409 · Balance 390,904.333 F1: Represents vesting of one-quarter of market share units granted on March 10, 2020. Row 2 · 2024-03-10 · Other · Disposed 3,687 · Balance 387,217.333 F2: Adjustment reflects shares disposed upon the vesting of market share units due to the performance factor. Row 3 · 2024-03-10 · Tax withholding · Disposed 10,088 · Balance 377,129.333 F3: Shares withheld for payment of taxes upon vesting of awards. Row 4 · 2024-03-10 · Exercise / conversion · Acquired 23,817 · Balance 400,946.333 F4: Represents vesting of one-quarter of market share units granted on March 10, 2021. Row 5 · 2024-03-10 · Other · Disposed 4,104 · Balance 396,842.333 F2: Adjustment reflects shares disposed upon the vesting of market share units due to the performance factor. Row 6 · 2024-03-10 · Tax withholding · Disposed 10,084 · Balance 386,758.333 F3: Shares withheld for payment of taxes upon vesting of awards. Row 7 · 2024-03-10 · Exercise / conversion · Acquired 142,904 · Balance 529,662.333 F5: Amount represents distribution of performance shares earned under the 2020-2022 Long-Term Performance Award. Row 8 · 2024-03-10 · Other · Disposed 49,745 · Balance 479,917.333 F6: Adjustment to Award based on the performance factor applied in accordance with the terms of the Award and certification of performance results by the Board. Row 9 · 2024-03-10 · Tax withholding · Disposed 47,651 · Balance 432,266.333 F3: Shares withheld for payment of taxes upon vesting of awards. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2024-03-10 | Direct | 0 |
Reported balance
After 2024-03-10 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-03-10 · Exercise / conversion · Disposed 23,409 · Balance 0 F7: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1: Represents vesting of one-quarter of market share units granted on March 10, 2020. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2025-03-10 | Direct | 23,818 |
Reported balance
After 2024-03-10 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-03-10 · Exercise / conversion · Disposed 23,817 · Balance 23,818 F7: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4: Represents vesting of one-quarter of market share units granted on March 10, 2021. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2026-03-10 | Direct | 44,429 |
Reported balance
After 2024-03-10 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-03-10 · Other · Disposed 22,214 · Balance 44,429 F8: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F9: Represents the cancellation of one-quarter of market share units granted on March 10, 2022 due to the 80% minimum payout factor not being achieved. F10: Twenty-five percent of these market share units will vest on each of the first, second, third and fourth anniversaries of the grant date. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2027-03-10 | Direct | 70,258 |
Reported balance
After 2024-03-10 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2024-03-10 · Other · Disposed 23,419 · Balance 70,258 F8: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%. F11: Represents the cancellation of one-quarter of market share units granted on March 10, 2023 due to the 80% minimum payout factor not being achieved. F10: Twenty-five percent of these market share units will vest on each of the first, second, third and fourth anniversaries of the grant date. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2024-03-10 | Direct | 0 |
Reported balance
After 2024-03-10 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2024-03-10 · Exercise / conversion · Disposed 142,904 · Balance 0 F12: Each performance share converts into one share of common stock upon distribution in the first quarter of 2024, subject to a Total Shareholder Return. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents vesting of one-quarter of market share units granted on March 10, 2020.
F2: Adjustment reflects shares disposed upon the vesting of market share units due to the performance factor.
F3: Shares withheld for payment of taxes upon vesting of awards.
F4: Represents vesting of one-quarter of market share units granted on March 10, 2021.
F5: Amount represents distribution of performance shares earned under the 2020-2022 Long-Term Performance Award.
F6: Adjustment to Award based on the performance factor applied in accordance with the terms of the Award and certification of performance results by the Board.
F7: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%.
F8: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 80% and the maximum payout factor is 225%.
F9: Represents the cancellation of one-quarter of market share units granted on March 10, 2022 due to the 80% minimum payout factor not being achieved.
F10: Twenty-five percent of these market share units will vest on each of the first, second, third and fourth anniversaries of the grant date.
F11: Represents the cancellation of one-quarter of market share units granted on March 10, 2023 due to the 80% minimum payout factor not being achieved.
F12: Each performance share converts into one share of common stock upon distribution in the first quarter of 2024, subject to a Total Shareholder Return.
STRYKER CORP
Report date May 06, 2026 · Filed May 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,530 |
Reported balance
After 2026-05-06 transaction · row 1
1 source rowRow 1 · 2026-05-06 · Grant · Acquired 762 · Balance 4,530 F1: Represents a grant of Restricted Stock Units (RSUs), which vest as to 100% of the shares on the earlier of (i) the date of the 2027 Annual Meeting of Shareholders of Stryker Corporation or (ii) May 6, 2027. F2: Each RSU represents a contingent right to receive one share of Stryker Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of Restricted Stock Units (RSUs), which vest as to 100% of the shares on the earlier of (i) the date of the 2027 Annual Meeting of Shareholders of Stryker Corporation or (ii) May 6, 2027.
F2: Each RSU represents a contingent right to receive one share of Stryker Common Stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2012 Filed Mar 9, 2012 02:27 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 3,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-007113 · doc4.xml · derivative · entry 6 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,430 Underlying: Common Stock, $0.10 par value · 3,353 shares Expires 2013-03-31 F7 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F8 · shares: Represents performance shares earned under the 2010-2012 Long-Term Performance Award. F7 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F7 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
| March 06, 2012 Filed Mar 9, 2012 02:27 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 8,811 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-007113 · doc4.xml · derivative · entry 5 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 8,811 shares Expires 2012-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2012. F1 · shares: Represents distribution of performance shares earned under the 2009-2011 Long-Term Performance Award. F5 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2012. F5 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2012. Read SEC document |
| March 06, 2012 Filed Mar 9, 2012 02:27 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 3,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-007113 · doc4.xml · derivative · entry 4 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,811 Underlying: Common Stock, $0.10 par value · 3,142 shares Expires 2012-03-31 F5 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2012. F6 · shares: Represents performance shares earned under the 2009-2011 Long-Term Performance Award. F5 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2012. F5 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2012. Read SEC document |
| March 06, 2012 Filed Mar 9, 2012 02:27 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 11,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-007113 · doc4.xml · derivative · entry 3 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,556 Underlying: Common Stock, $0.10 par value · 11,556 shares Expires 2016-03-06 F3 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the vesting date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. F4 · derivative.expiration_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| March 06, 2012 Filed Mar 9, 2012 02:27 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,204 | $32.33 | $103,585.32 |
DisclosureSEC source: 0001225208-12-007113 · doc4.xml · nonDerivative · entry 2 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,702.018 F2 · shares: Shares withheld for payment of taxes upon distribution of the 2009-2011 Long-Term Performance Award. Read SEC document |
| March 06, 2012 Filed Mar 9, 2012 02:27 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 8,811 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-007113 · doc4.xml · nonDerivative · entry 1 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,906.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents distribution of performance shares earned under the 2009-2011 Long-Term Performance Award. Read SEC document |
| March 04, 2012 Filed Mar 6, 2012 00:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 1,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-006724 · doc4.xml · derivative · entry 14 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 1,517 shares Expires 2012-03-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F7 · derivative.exercise_date: Represents vesting of one-quarter of restricted stock units granted on March 4, 2008. The award has fully vested. F7 · derivative.expiration_date: Represents vesting of one-quarter of restricted stock units granted on March 4, 2008. The award has fully vested. Read SEC document |
| March 04, 2012 Filed Mar 6, 2012 00:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 552 | $32.59 | $17,989.68 |
DisclosureSEC source: 0001225208-12-006724 · doc4.xml · nonDerivative · entry 10 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,095.018 F6 · shares: Shares withheld for payment of taxes upon vesting of restricted stock units. Read SEC document |
| March 04, 2012 Filed Mar 6, 2012 00:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 1,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-006724 · doc4.xml · nonDerivative · entry 9 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,647.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · shares: Represents vesting of one-quarter of restricted stock units granted on March 4, 2008. The award has fully vested. Read SEC document |
| March 03, 2012 Filed Mar 6, 2012 00:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 1,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-006724 · doc4.xml · derivative · entry 13 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,851 Underlying: Common Stock, $0.10 par value · 1,851 shares Expires 2013-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F5 · derivative.exercise_date: Represents vesting of one-quarter of restricted stock units granted on March 3, 2009. The balance of the award is scheduled to vest on the fourth anniversary of the grant date. F5 · derivative.expiration_date: Represents vesting of one-quarter of restricted stock units granted on March 3, 2009. The balance of the award is scheduled to vest on the fourth anniversary of the grant date. Read SEC document |
| March 03, 2012 Filed Mar 6, 2012 00:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 673 | $32.59 | $21,933.07 |
DisclosureSEC source: 0001225208-12-006724 · doc4.xml · nonDerivative · entry 8 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,130.018 F6 · shares: Shares withheld for payment of taxes upon vesting of restricted stock units. Read SEC document |
| March 03, 2012 Filed Mar 6, 2012 00:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 1,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-006724 · doc4.xml · nonDerivative · entry 7 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,803.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Represents vesting of one-quarter of restricted stock units granted on March 3, 2009. The balance of the award is scheduled to vest on the fourth anniversary of the grant date. Read SEC document |
| March 02, 2012 Filed Mar 6, 2012 00:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 1,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-006724 · doc4.xml · derivative · entry 12 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,394 Underlying: Common Stock, $0.10 par value · 1,197 shares Expires 2014-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the vesting date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 2, 2010. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. F4 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 2, 2010. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. Read SEC document |
| March 02, 2012 Filed Mar 6, 2012 00:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 575 | $32.59 | $18,739.25 |
DisclosureSEC source: 0001225208-12-006724 · doc4.xml · nonDerivative · entry 6 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,952.018 F3 · shares: Shares withheld for payment of taxes upon vesting of market share units. Read SEC document |
| March 02, 2012 Filed Mar 6, 2012 00:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 384 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-006724 · doc4.xml · nonDerivative · entry 5 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,527.018 F2 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 02, 2012 Filed Mar 6, 2012 00:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 1,197 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-006724 · doc4.xml · nonDerivative · entry 4 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,143.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · shares: Represents vesting of one-quarter of market share units granted on March 2, 2010. The balance of the award is scheduled to vest in two equal installments on the third and fourth anniversaries of the grant date. Read SEC document |
| March 01, 2012 Filed Mar 6, 2012 00:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 1,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-006724 · doc4.xml · derivative · entry 11 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,482 Underlying: Common Stock, $0.10 par value · 1,493 shares Expires 2015-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the vesting date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1 · derivative.exercise_date: Represents vesting of one-quarter of market share units granted on March 1, 2011. The balance of the award is scheduled to vest in three equal installments on the second, third, and fourth anniversaries of the grant date. F1 · derivative.expiration_date: Represents vesting of one-quarter of market share units granted on March 1, 2011. The balance of the award is scheduled to vest in three equal installments on the second, third, and fourth anniversaries of the grant date. Read SEC document |
| March 01, 2012 Filed Mar 6, 2012 00:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 690 | $32.64 | $22,521.60 |
DisclosureSEC source: 0001225208-12-006724 · doc4.xml · nonDerivative · entry 3 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,946.018 F3 · shares: Shares withheld for payment of taxes upon vesting of market share units. Read SEC document |
| March 01, 2012 Filed Mar 6, 2012 00:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 404 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-006724 · doc4.xml · nonDerivative · entry 2 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,636.018 F2 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Read SEC document |
| March 01, 2012 Filed Mar 6, 2012 00:43 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 1,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-006724 · doc4.xml · nonDerivative · entry 1 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,232.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents vesting of one-quarter of market share units granted on March 1, 2011. The balance of the award is scheduled to vest in three equal installments on the second, third, and fourth anniversaries of the grant date. Read SEC document |
| January 03, 2012 Filed Jan 4, 2012 23:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-000650 · doc4.xml · derivative · entry 3 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock, $0.10 par value · 7,500 shares Expires 2015-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F3 · derivative.exercise_date: Represents vesting of one-quarter of restricted stock units granted on January 3, 2011. The balance of the award is scheduled to vest in three equal installments on the second, third and fourth anniversaries of the grant date. F3 · derivative.expiration_date: Represents vesting of one-quarter of restricted stock units granted on January 3, 2011. The balance of the award is scheduled to vest in three equal installments on the second, third and fourth anniversaries of the grant date. Read SEC document |
| January 03, 2012 Filed Jan 4, 2012 23:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,579 | $35.01 | $125,300.79 |
DisclosureSEC source: 0001225208-12-000650 · doc4.xml · nonDerivative · entry 2 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,739.018 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock units. Read SEC document |
| January 03, 2012 Filed Jan 4, 2012 23:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-12-000650 · doc4.xml · nonDerivative · entry 1 Caforio Giovanni · CIK 0001533201 · Pres., US Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,318.018 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.